AsclepiX Therapeutics, Inc., a biopharmaceutical company focused on developing novel peptide therapies, including AXT107 for retinal disease and novel peptides…
AXT107 exhibited a dual mechanism of action as a monotherapy, disrupting a key component of the Vascular Endothelial Growth Factor…